Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

AMRN, ALLT, ALTH, SAVW, EEGI - Stock News From DrStockPick.com!

drstock-2-3

signup3m

http://pennyomega.com/img/eegi_new.jpg

Eline Entertainment Group, Inc. (PINK SHEETS:EEGI) subsidiary Let The Good Times Roll, Inc. is pleased to announce a joint venture with the Hard Rock Hotel and Casino.

This new incentivized agreement with provides LTGTR riders with $25-$35 in gaming chips and a $5 food voucher when booked for the Hard Rock Casino. LTGTR, will experiment and plans to start running shuttles to the Hard Rock, charging $25-30 for round trip services. The deal is conditionally approved and subject to pending insurance verification. The company sees this as a simple administrative task, and to be resolved shortly.

Preliminary research shows strong support with the company running 14 casino runs a week, with each shuttle generating an average of $750 in revenue with 60-70% in gross profit.

LTGTR, which provides the premier "party on wheels" experience, intends to increase revenue streams through adding standard shuttle routes and joint ventures with popular venues such as this one. LTGTR has begun by creating Luxury Shuttles designed to travel from regionally isolated areas to populated hotspots. This includes a division of "Safety Shuttles" geared towards college students, intended to give "of-age" students the ability to enjoy nightlife without the hassle of designated drivers, parking fees, etc. These shuttles will run along a scheduled route, delivering riders to pre-contracted venues which provide customer discounts and/or incentives. The Company is currently in talks to purchase competing businesses with synergy to the new business model of LTGTR.

****************************************************

http://pennyomega.com/img/savw.jpg

SavWatt USA, Inc. (OTC:SAVW), pioneers in LED lighting, announced that beginning 1Q 2011, SavWatt will be selling LED T-8 florescent tube replacements assembled in the USA. SavWatt's 16 Watt , 4 foot, T-8 LED tube will replace a typical 40 Watt florescent tube (includes ballast), providing immediate energy savings of 60%, which does not include savings for service and replacement costs. Based on an average USA energy cost of 15 cents per kilowatt, the tube has a 24 month payback.

Features of SavWatt's LED Tube Lights.

* Energy Saving - SavWatt LED tubes consume low power. Power efficiency reaches 90 percent, with energy saving of 60% compared with traditional florescent tubes.
* Environmental Friendly - SavWatt LED tubes contain no ultraviolet, infrared ray radiation, mercury or heat from the illumination.
* Long Life Span - SavWatt LED tube has a 50,000 - 80,000 hours life span compared to 8,000 hours for traditional florescent tubes. Good heat dissipation techniques are achieved through the use of SavWatt's Eco-Watt technology.
* Ultra Bright - using high illumine LITKY LED's separate SavWatt from others.
* Stable - SavWatt's superior component quality control and 48 hour USA burn in procedures makes it top in its class.

Sam Abecassis, SavWatt's VP of Product Development commented, "We have worked hard over the last 2 years to develop and bring to market a UL approved true T-8 high quality Led tube. Our Eco-Watt technology and LITKY LED's make us shine above the rest. We have listened to our distributors and by assembling here in the USA we now will be able to handle the faster to market demand and quality concerns."

****************************************************

Allos Therapeutics, Inc. (Nasdaq:ALTH) announced that five abstracts, describing FOLOTYN® (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year’s 52nd American Society of Hematology (NYSE:ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida. “At ASH, new and updated analyses expand our understanding of the clinical data for FOLOTYN in patients with T-cell lymphoma, including data from the pivotal Phase 2 PROPEL study in relapsed or refractory peripheral T-cell lymphoma and transformed mycosis fungoides, as well as updated results from the Phase 1 dose-finding study in relapsed or refractory cutaneous T-cell lymphoma,” said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics.

Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics.

****************************************************

Allot Communications Ltd. (Nasdaq:ALLT) a leading supplier of service optimization and revenue generation solutions for fixed and mobile broadband service providers worldwide, announced that the Tel-Aviv Stock Exchange (”TASE”) has approved the dual listing of the Company’s ordinary shares on the TASE beginning at market open on December 21, 2010, under the ticker symbol ALLT. The Company’s ordinary shares will continue to be listed on the NASDAQ Global Select Market in the United States, and Allot will remain subject to the rules and regulations of NASDAQ and of the U.S. Securities and Exchange Commission. Allot will host a welcoming ceremony on December 20, 2010 at 09:30 AM Israel time at the Tel-Aviv Stock Exchange Visitor Center at 54 Ahad Ha’am Street, Tel Aviv. Rami Hadar, President and CEO of Allot, and Nachum Falek, CFO, will speak and will be available for questions.

Allot Communications Ltd. provides Internet protocol service optimization solutions for DSL, wireless and mobile broadband carriers, cable operator service providers, and enterprises in Europe, the Middle East, Africa, the Americas, Asia, and Oceania.

****************************************************

Amarin Corporation plc (Nasdaq:AMRN) a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101. The MARINE study, investigating AMR101 as a treatment for very high triglycerides (500 mg/dL), met its primary efficacy endpoints as defined in the clinical trial protocol and demonstrated a positive safety profile. The Company believes that AMR101 has the potential to be the best-in-class product for this indication and that the MARINE study results may support additional patentable claims that could further protect the Company’s rights to this product through 2030.

Amarin Corporation plc operates as a biopharmaceutical company with a focus on cardiovascular diseases. Its cardiovascular programs focus in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Eline Entertainment Group, Inc. (OTCPK:EEGI)

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for SavWatt USA, Inc. (OTC:SAVW)

drstbc